IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Inclusion Criteria: 1. Males and Females, age ≥18 years and ≤75 years; 2. Histologically or cytologically confirmed primary non-squamous NSCLC: * Stage IB, II, IIIA or IIIB (N2) NSCLC (per AJCC8); * No administration of any anti-NSCLC therapy in the pre-operative period; * Be able to undergo the radical resection; Pulmonary function capacity capable of tolerating the proposed lung resection according to the surgeon. 3. Participants without EGFR mutations or ALK translocation; 4. At least 1 measurable lesion per RECIST v1.1; 5. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1; 6. Adequate organ function confirmed at screening period. Exclusion Criteria: 1. Histologically confirmed the presence of small cell lung cancer, neuroendocrine carcinoma, sarcoma, salivary gland tumor, and mesenchymal tumor components, or mixed NSCLC with predominant squamous cell carcinoma features; 2. Tumor invasion of surrounding important structures, which is symptomatic or medical intervention indicated; 3. Pancoast tumor; 4. Malignant tumor nodule in the contralateral lung lobe; 5. Participants with known or suspected brain metastases or other distant metastases; 6. Participants who received Chinese herbal medicines, proprietary Chinese medicines with anti-tumor indications, or immunomodulatory drugs within 2 weeks prior to the first dose of the study drug; 7. Participants with a condition requiring systemic treatment with corticosteroids or is receiving any other form of immunosuppressive therapy within 7 days prior the first dose of the study drug; 8. History of any arterial thromboembolic event within 6 months prior to the first dose of the study drug; 9. History of deep vein thrombosis, pulmonary embolism, or any other serious venous thromboembolism within 3 months prior to the first dose of study drug; 10. History of pneumonitis requiring corticosteroid therapy, or history of clinically significant lung diseases or who are suspected to have these diseases by imaging during the screening period; 11. Active or uncontrolled diseases or conditions; 12. History of immunodeficiency disease; 13. Participants with active autoimmune disease requiring systemic treatment within 2 years prior to the first dose of the study drug.